Title | Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M, Hirschhorn D, Budhu S, Amisaki M, Arniella M, Redmond D, Chaft J, Forde PM, Gainor JF, Hellmann MD, Balachandran V, Shah S, Smith KN, Pardoll D, Elemento O, Wolchok JD, Merghoub T |
Journal | J Exp Med |
Volume | 219 |
Issue | 6 |
Date Published | 2022 Jun 06 |
ISSN | 1540-9538 |
Keywords | Animals, CD4 Antigens, CD4-Positive T-Lymphocytes, CD8 Antigens, CD8-Positive T-Lymphocytes, Cell Differentiation, Cell Lineage, Melanoma, Mice, T-Lymphocyte Subsets |
Abstract | Transcription factors ThPOK and Runx3 regulate the differentiation of "helper" CD4+ and "cytotoxic" CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the expression of either the CD4 or CD8 co-receptor. Despite the expectation that these cell fates are mutually exclusive and that mature CD4+CD8+ double positive (DP) T cells are present in healthy individuals and augmented in the context of disease, yet their molecular features and pathophysiologic role are disputed. Here, we show DP T cells in murine and human tumors as a heterogenous population originating from SP T cells which re-express the opposite co-receptor and acquire features of the opposite cell type's phenotype and function following TCR stimulation. We identified distinct clonally expanded DP T cells in human melanoma and lung cancer by scRNA sequencing and demonstrated their tumor reactivity in cytotoxicity assays. Our findings indicate that antigen stimulation induces SP T cells to differentiate into DP T cell subsets gaining in polyfunctional characteristics. |
DOI | 10.1084/jem.20212169 |
Alternate Journal | J Exp Med |
PubMed ID | 35604411 |
PubMed Central ID | PMC9130031 |
Grant List | R37 CA251447 / CA / NCI NIH HHS / United States T32 CA009110 / CA / NCI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States / CRI / Cancer Research Institute / United States R01 CA056821 / CA / NCI NIH HHS / United States P30 CA008748 / NH / NIH HHS / United States |